Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neo ALTTO: Lapatinib and/or Trastuzumab in HER2+ Breast Cancer
NCT00553358Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2008
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of lapatinib in HER2-positive breast cancer, sponsored by Novartis. Started Jan 2008; status: completed.
02
Drugs
lapatinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT00553358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00553358.